Management of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream

Area of Science:

• Dermatology
• Rare Diseases

Background:

• Benign Familial Pemphigus, also known as Hailey-Hailey Disease (HHD), is a rare, chronic blistering skin disorder.
• Current treatments for HHD focus on symptom management but often prove insufficient for severe or refractory cases.

Purpose of the Study:

• To evaluate the efficacy of ruxolitinib cream as a novel therapeutic option for a patient with refractory Hailey-Hailey Disease.
• To highlight the challenges in managing persistent HHD flares and the importance of exploring alternative treatments.

Main Methods:

• Case presentation of a 72-year-old female patient diagnosed with refractory Hailey-Hailey Disease.
• Administration of ruxolitinib 1.5% cream after conventional therapies (antibiotics, corticosteroids) failed to control disease flares.

Main Results:

• The patient experienced significant symptom improvement after initiating treatment with ruxolitinib 1.5% cream.
• Ruxolitinib cream demonstrated a positive response in managing refractory HHD symptoms.

Conclusions:

• This case suggests that ruxolitinib cream may be a viable and effective treatment option for Hailey-Hailey Disease.
• Further clinical investigation is warranted to confirm the efficacy and safety of ruxolitinib in managing HHD and improving patient outcomes.